Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares
Simply Wall St
Sun, January 18, 2026 at 8:18 AM EST
2 min read
In this article:
Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) recently shelled out US$82k to buy stock, at US$1.68 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign.
Acrivon Therapeutics Insider Transactions Over The Last Year
In fact, the recent purchase by Peter Blume-Jensen was the biggest purchase of Acrivon Therapeutics shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of US$1.98. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months Acrivon Therapeutics insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
View our latest analysis for Acrivon Therapeutics
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Acrivon Therapeutics
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Acrivon Therapeutics insiders own 8.0% of the company, worth about US$5.0m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
So What Do The Acrivon Therapeutics Insider Transactions Indicate?
It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Acrivon Therapeutics insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Acrivon Therapeutics. Case in point: We've spotted 5 warning signs for Acrivon Therapeutics you should be aware of, and 3 of these are potentially serious.
Story Continues
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments